143587-37-5

Basic information

• Product Name: Benzoyl chloride, 3-ethynyl- (9CI)
• Synonyms: Benzoyl chloride, 3-ethynyl- (9CI)
• CAS NO: 143587-37-5
• Molecular Formula: C₉H₅ClO
• Molecular Weight: 164.5884
• Product Categories: ACIDHALIDE
• Mol File: 143587-37-5.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzoyl chloride, 3-ethynyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoyl chloride, 3-ethynyl- (9CI)(143587-37-5)
• EPA Substance Registry System: Benzoyl chloride, 3-ethynyl- (9CI)(143587-37-5)

Safety Data

• Hazardous Substances Data: 143587-37-5(Hazardous Substances Data)

Upstream product

• 108-95-2 phenol 
• 10601-99-7 3-ethynylbenzoic acid 
• 77123-59-2 methyl 3-<(trimethylsilyl)ethynyl>benzoate 
• 618-91-7 methyl 3-iodo-benzoate 
• 618-51-9 3-Iodobenzoic acid 
• 10602-06-9 methyl 3-ethynylbenzoate 

Downstream Products

• 1198118-74-9 3-ethynyl-N,N-diisopropylbenzamide 
• 1609678-68-3 N-{4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-ethynylbenzamide 

Relevant articles and documents

Cys–Cys and Cys–Lys Stapling of Unprotected Peptides Enabled by Hypervalent Iodine Reagents

Easy access to a wide range of structurally diverse stapled peptides is crucial for the development of inhibitors of protein-protein interactions. Herein, we report bis-functional hypervalent iodine reagents for two-component cysteine-cysteine and cysteine-lysine stapling yielding structurally diverse thioalkyne linkers. This stapling method works with unprotected natural amino acid residues and does not require pre-functionalization or metal catalysis. The products are stable to purification and isolation. Post-stapling modification can be accessed via amidation of an activated ester, or via cycloaddition onto the formed thioalkyne group. Increased helicity and binding affinity to MDM2 was obtained for a i,i+7 stapled peptide.

Development of Alkyne-Containing Pyrazolopyrimidines to Overcome Drug Resistance of Bcr-Abl Kinase

Despite the success of imatinib at inhibiting Bcr-Abl and treating chronic myelogenous leukemia (CML), resistance to the therapy occurs over time in patients. In particular, the resistance to imatinib caused by the gatekeeper mutation T315I in Bcr-Abl remains a challenge in the clinic. Inspired by the successful development of ponatinib to curb drug resistance, we hypothesize that the incorporation of an alkyne linker in other heterocyclic scaffolds can also achieve potent inhibition of Bcr-AblT315I by allowing for simultaneous occupancy of both the active site and the allosteric pocket in the Abl kinase domain. Herein, we describe the design, synthesis, and characterization of a series of alkyne-containing pyrazolopyrimidines as Bcr-Abl inhibitors. Our results demonstrate that some alkyne-containing pyrazolopyrimidines potently inhibit not only AblT315I in vitro but also Bcr-AblT315I in cells. These pyrazolopyrimidines can serve as lead compounds for future development of novel targeted therapy to overcome drug resistance of CML.

SUBSTITUTED PHENYLETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX

The present invention is directed to a substituted phenylethynylgold-nitrogen-containing heterocyclic carbene complex represented by the formula (1) or (2): wherein L represents a nitrogen-containing heterocyclic carbene ligand, and X represents an alkyl